SEC Company Response from BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149) (BIVI) — Nov 7, 2013
BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149)
Date: Nov. 7, 2013 · CIK: 0001580149 · Accession: 0001548233-13-000022
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-190635
Letter
Elliot Ehrlich
Chief Executive Officer
NanoAntibiotics, Inc.
9511 Collins Ave., Suite 807
November 7, 2013
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549-0213
Fax: (703) 813-6968
Re: NanoAntibiotics, Inc.
Request for Acceleration of Registration Statement on Form S-1
File No. 333-190635
Ladies and Gentlemen:
NanoAntibiotics, Inc., a Nevada corporation (the “Company”) hereby requests acceleration of the effectiveness of its Registration Statement on Form S-1 (File No. 333-190635), originally filed with the U.S. Securities and Exchange Commission (the “Commission”) on August 15, 2013, as amended and filed as Amendment No. 1 to Form S-1 on September 26, 2013, as further amended and filed as Amendment No. 2 to Form S-1 on October 15, 2013 and as further amended and filed as Amendment No. 3 to Form S-1 on November 5, 2013, to 2:00PM EST on November 8, 2013, or as soon thereafter as practicable. The Company hereby acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please direct any questions or comments regarding this filing to Matthew Ogurick, Esq. at (305) 539-3352 of K&L Gates LLP, legal counsel to the Company.
Sincerely,
/s/ Elliot Ehrlich
Show Raw Text
CORRESP
1
filename1.htm
Elliot Ehrlich
Chief Executive Officer
NanoAntibiotics, Inc.
9511 Collins Ave., Suite 807
November 7, 2013
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549-0213
Fax: (703) 813-6968
Re: NanoAntibiotics, Inc.
Request for Acceleration of Registration Statement on Form S-1
File No. 333-190635
Ladies and Gentlemen:
NanoAntibiotics, Inc.,
a Nevada corporation (the “Company”) hereby requests acceleration of the effectiveness of its Registration Statement
on Form S-1 (File No. 333-190635), originally filed with the U.S. Securities and Exchange
Commission (the “Commission”) on August 15, 2013, as amended and filed as Amendment No. 1 to Form S-1 on September
26, 2013, as further amended and filed as Amendment No. 2 to Form S-1 on October 15, 2013 and as further amended and filed as Amendment
No. 3 to Form S-1 on November 5, 2013, to 2:00PM EST on November 8, 2013, or as soon thereafter as practicable. The Company hereby
acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority,
declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy
of the disclosure in the filing; and
· the Company may not assert this action as a defense in any proceeding initiated
by the Commission or any person under the federal securities laws of the United States.
Please direct any
questions or comments regarding this filing to Matthew Ogurick, Esq. at (305) 539-3352 of K&L Gates LLP, legal counsel to the
Company.
Sincerely,
/s/ Elliot Ehrlich
Elliot Ehrlich
Chief Executive Officer